AI in COPD diagnosis can support case finding, spirometry interpretation and equity while GOLD 2026 highlights validation and guideline gaps.
Astegolimab for COPD was evaluated in the ALIENTO and ARNASA trials to assess its efficacy and safety in patients with frequent exacerbations.
Maternal smoking and CC16 are linked to impaired lung development, lung function decline and emphysema progression, increasing lifelong COPD risk.
Expiratory flow-volume curve concavity predicts future respiratory symptoms but shows lower discriminatory accuracy for COPD incidence than FEV1/FVC.
Gut-lung axis microbiome analysis in stable COPD reveals distinct gut and lung microbiomes associated with airflow limitation, exacerbations and ICS use
BMI genetic factors and COPD are associated with decreased emphysema and increased airway wall thickness across quantitative and visual imaging phenotypes
2026 GOLD update: key recommendations for primary care on COPD diagnosis, assessment, prevention, treatment, exacerbations and emerging technologies.
2026 GOLD International COPD Conference, November 5–6 in Philadelphia. Discover Session 4 on the diagnosis, assessment and management of COPD.
Explore the Respiratory Preceptorship 2026 at Món Clínic Barcelona, featuring expert sessions on asthma, COPD, pulmonary rehabilitation and respiratory medicine.
Learn why earlier COPD diagnosis and better clinical control during follow-up are essential to reduce exacerbations, improve quality of life and optimise patient outcomes.
